PATENT CLAIM ANALYSIS

Application Number: 15947840
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "267000"]

Abstract:
Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.

Claim (Index 24):
The method according to  claim 21 , wherein the cancer has a histone H3 mutation, wherein the histone H3 mutation is H3.3 K27M or H3.1 K27M.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 91.0
- Lexical Diversity: 1.80882
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15527982', '14290642', '13418242', '14049950', '14692597']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7551391953098272
- 35 USC 102 Novelty (BERT): 0.5081304702897492
- Combined Prediction Score: 0.7304383228078194
- Mean Citation Score: 216.95378
- Max Citation Score: 256.38425
- Similarity Product: 175.3016086500287

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test